Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.

At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets.

"We are very pleased to welcome Anna to AcuCort. Her solid experience in business development, international partnerships and commercialisation within life science will be an important addition to our growth journey. Anna's drive, structured approach and strategic ability make her an excellent fit for our team," says Jonas Jönmark, CEO of AcuCort.

"I am very much looking forward to joining AcuCort and contributing to the company's continued growth and commercial success," says Anna Chérouvrier Hansson, incoming Business Development Director.

For further information, please contact: 
Jonas Jönmark, CEO, AcuCort AB
Phone: +46 70 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.